Home › CHMP Issues Positive Opinion for Tablet Formulation of Mercks NOXAFIL (posaconazole)
 

Keywords :   


CHMP Issues Positive Opinion for Tablet Formulation of Mercks NOXAFIL (posaconazole)

2014-02-28 14:30:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a new, investigational tablet formulation of NOXAFIL (posaconazole). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: issues positive opinion formulation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
05.07Simplestream reveals preferred technology partnership with Freely
05.07TikTok launches on whaleOS 3-powered TVs
05.07Hurricane Beryl Graphics
05.07Hurricane Beryl Forecast Discussion Number 28
05.07Tropical Depression Aletta Graphics
More »